LUMIZYME
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUMIZYME (LUMIZYME).
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA), which hydrolyzes lysosomal glycogen. It provides exogenous enzyme to reduce accumulation of glycogen in lysosomes.
| Metabolism | Degraded via proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes. |
| Excretion | Eliminated via reticuloendothelial system; no significant renal or biliary excretion. <5% recovered unchanged in urine. |
| Half-life | Terminal half-life: 1.1–3.5 hours (mean 2.2 hours) after IV infusion; due to rapid uptake into lysosomes, shorter than many enzymes. |
| Protein binding | Minimal protein binding (<5%); primarily bound to mannose-6-phosphate receptors on cell surfaces. |
| Volume of Distribution | 0.24–0.35 L/kg; reflects limited distribution to tissues expressing mannose-6-phosphate receptors (e.g., liver, muscle). |
| Bioavailability | Only administered intravenously; bioavailability 100% by IV route. Not bioavailable orally (proteolytic degradation). |
| Onset of Action | IV infusion: Reduction in urinary GAGs observed within 2–4 weeks; clinical improvement in hepatomegaly and endurance over 6 months. |
| Duration of Action | Tissue lysosomal enzyme activity persists for weeks; clinical effects require repeated dosing every 2 weeks. |
5 mg/kg administered intravenously once every 2 weeks.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Same as adult: 5 mg/kg intravenously once every 2 weeks. |
| Geriatric use | No specific dose adjustment required for elderly patients; dose based on body weight. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LUMIZYME (LUMIZYME).
| Breastfeeding | No data on presence in human milk; M/P ratio unknown. Alglucosidase alfa is a large protein likely degraded in GI tract; risk to infant is considered low. |
| Teratogenic Risk | Insufficient human data; animal studies show no teratogenic effects at clinically relevant doses (alglucosidase alfa does not cross placenta substantially). Limited risk expected across all trimesters. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Severe hypersensitivity to alglucosidase alfa or any inactive ingredient"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis, urticaria, and angioedema","Infusion-associated reactions (IARs), may require premedication and slowed infusion rate","Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome","Immunogenicity: neutralising antibodies may reduce efficacy","Cardiac complications: risk of arrhythmias and cardiac arrest, especially in infants"] |
Loading safety data…
| Monitor maternal vital signs and infusion reactions. Fetal assessment per standard obstetric care; no specific fetal monitoring required. |
| Fertility Effects | No effects on fertility observed in animal studies; human data unavailable. |